Key Highlights
- $12 million investment agreement with Lind Global Fund II LP to accelerate technology development.
- Focus on four core work streams: hardware development, clinical research, algorithm development, and IP expansion.
- Preparation for FDA clearance for the non-invasive wearable continuous glucose monitor.
Source: Business Wire
Notable Quotes
- “This investment will enable Know Labs to accelerate development… We remain focused on validating the performance of the Know Labs proprietary radiofrequency dielectric sensor.” – Ron Erickson, CEO and Chairman at Know Labs
- “Know Labs has demonstrated success… We are pleased to invest in Know Labs to support its growth.” – Phillip Valliere Managing Director at The Lind Partners
SoHC's Take
This funding agreement between Know Labs and Lind signifies a pivotal moment for non-invasive medical diagnostics. The $12 million investment, focusing on accelerating Know Labs’ innovative work, highlights the growing interest and belief in the potential of non-invasive technologies. With a particular emphasis on developing a wearable glucose monitor, Know Labs is on the brink of revolutionizing diabetes management by making glucose monitoring easier, more accessible, and non-intrusive. This move not only benefits Know Labs but also represents a broader shift towards less invasive, technology-driven healthcare solutions, promising a significant impact on patient care and medical practices.
